Document is current
Any future updates will be listed below
-
Authors
Jayakrishnan, Thejus
Mariam, Arshiya
Farha, Nicole
Rotroff, Daniel M.
Aucejo, Federico
Barot, Shimoli V.
Conces, Madison
Nair, Kanika G.
Krishnamurthi, Smitha S.
Schmit, Stephanie L.
Liska, David
Khorana, Alok A.
Kamath, Suneel D.
-
Funding
Funding for this research was provided by:
The Sondra and Stephen Hardis Chair in Oncology Research
- License Information
-
More Information
Article History
Received: 19 October 2023
Accepted: 14 February 2024
First Online: 21 February 2024
Competing interests
: Thejus Jayakrishnan – No disclosures Nicole Farha – No disclosures Arshiya Mariam – No disclosures Daniel M. Rotroff – Equity stake in Clarified Precision Medicine, LLC. Received research support from Novo Nordisk, consulting honoraria from Pharmazaam, LLC, and Interpares Biomedicine owns intellectual property related to the detection of type-2 diabetes, chronic liver disease, and liver cancer Federico Aucejo – No disclosures Shimoli V. Barot – No disclosures Madison Conces – No disclosures Kanika G. Nair – No disclosures Smitha S. Krishnamurthi -- Consulting or Advisory Role––Array BioPharma, Research funding- Bristol Myers Squibb, Pfizer, Aravive, Natera Stephanie L. Schmit – No disclosures David Liska – Consulting or Advisory Role- Olympus Medical Systems, Research funding – Merck, Freenome Suneel D. Kamath – Consulting or advisory role: Exelixis, Guardant Health. Tempus, SeaGen, Foundation Medicine. Alok A. Khorana has been paid honoraria - Janssen, Sanofi, BMS, Anthos, Pfizer, Bayer, Nektar, and Medscape. Consulting or advisory role: Janssen, Sanofi, BMS, Anthos, Pfizer, Bayer, Nektar, and Medscape
